Recently, multitarget therapeutic strategies have been devised to target acetylcholinesterase, butyrylcholinesterase and, for example, monoamine oxidase B. Because, in Alzheimer’s disease brain, the acetylcholinesterase activity is maintained or repressed, while the butyrylcholinesterase activity tends to increase, the discovery of drugs inhibiting both enzymes as well as that of selective butyrylcholinesterase inhibitors is advisable. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.